Major Alzheimer’s disease research centers across the country face a $65m funding gap amid a Trump administration-imposed delay, with at least one struggling to retain highly trained staff.
Although courts have ruled a government-wide funding freeze is illegal, the administration has managed to delay research funding by canceling scientific meetings and failing to publish forthcoming meetings in the Federal Register, both which are legally required.
